How does basiliximab block T-cell activation involved in transplant rejection?

Basiliximab binds with high affinity to CD25 on activated T-lymphocytes, preventing interleukin-2 binding to its receptor and thereby blocking a critical signal for T-cell proliferation involved in transplant rejection.